Conjugates of titanocene with non-steroidal anti-inflammatory drugs: synthesis, unusual NMR characteristics, stability and cytotoxicity-Reference-Cited by-同舟云学术

Conjugates of titanocene with non-steroidal anti-inflammatory drugs: synthesis, unusual NMR characteristics, stability and cytotoxicity

Published:2024 Issue:4 Volume:48 Page:1650-1660
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Guk Dmitry A.¹^ORCID,Gibadullina Karina R.¹,Moiseeva Anna A.¹,Grishin Yuri K.¹,Roznyatovsky Vitaly A.¹,Prosuntsova Daria S.¹^ORCID,Ananieva Irina A.¹^ORCID,Gandalipov Erik R.²,Shtil Alexander A.¹³⁴,Beloglazkina Elena K.¹^ORCID

Affiliation:

1. Chemistry Department, Lomonosov Moscow State University, 1/3 Leninskie Gory, Moscow 119991, Russia

2. International Institute of Solution Chemistry of Advanced Materials and Technologies, ITMO University, 9 Lomonosov Street, 191002 Saint-Petersburg, Russia

3. Blokhin National Medical Research Center of Oncology, 24 Kashirskoye shosse, 115522 Moscow, Russia

4. Institute of Cyber Intelligence Systems, National Research Nuclear University MEPhI, 31 Kashirskoye shosse, 115409 Moscow, Russia

Abstract

Titanocene conjugates with four different non-steroidal anti-inflammatory drugs (flurbiprofen, naproxen, ibuprofen, and diclofenac; NSAIDs) were obtained and studied for the first time.

Funder

Russian Science Foundation

Lomonosov Moscow State University

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NJ/D3NJ04845D

Reference55 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Platinum neurotoxicity pharmacogenetics

4. Mechanisms of Cisplatin Nephrotoxicity

5. The status of platinum anticancer drugs in the clinic and in clinical trials